CANABID-LD

The CANABID-LD study is looking at how a medication called cannabidiol affects adults who have certain rare and severe epilepsy conditions

Illustration of a brain with electric pulses

CANABID-LD

The CANABID-LD study is looking at how a medication called cannabidiol affects adults who have certain rare and severe epilepsy conditions

The CANABID-LD study is looking at how a medication called cannabidiol (brand name Epidyolex) affects adults who have certain rare and severe epilepsy conditions (Dravet syndrome, Lennox-Gastaut syndrome and tuberous sclerosis complex). People with these conditions often have intellectual disabilities and have difficulties with challenging behaviours. Researchers want to understand whether this medication helps reduce challenging behaviours, seizure frequency and improves quality of life for these individuals.

This study is not a clinical trial but an observational one, which means researchers will monitor and collect data from people who are scheduled to start the medication as part of their usual care.

The study is being led by Professor Rohit Shankar from the ��, supported by the Peninsula Clinical Trials Unit (PenCTU) , and funded by Jazz Pharmaceuticals. Around 60 participants will be recruited from about 10 different NHS locations in England and Wales.

If you would like to learn more about the study, please get in touch with us at canabid.penctu@plymouth.ac.uk

Study progress

Swansea Hospital are our fourth site and are now recruiting
Birmingham Community Healthcare are now recruiting – congratulations on being our third site to open
The second site has opened – we’re delighted to have the team at University Hospitals of Leicester on board
CANBABID-LD is now open to recruitment – congratulations to Leeds Teaching Hospitals on being the first site to open
CANABID-LD has received HRA and ethics approval – congratulations to the study team